Nama's AI scorecard currently rates Neogen Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NEOG's P/E ratio?

Neogen trades at a trailing price-to-earnings ratio of 32.7.

When does NEOG report earnings?

Neogen's next scheduled report is on Jan 7, 2027. Analysts expect EPS of $0.06.

What is the NEOG price target?

The median analyst price target from 3 analysts is $14.00, with a range of $14.00 – $14.00.

Is NEOG Shariah compliant?

Nama's AAOIFI-style screen reads Neogen as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Neogen (NEOG)

Healthcare · Medical Devices · NASDAQ

Neogen (NEOG) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $2.57B, a trailing price-to-earnings ratio of 32.7 and a free-cash-flow yield of 1.3%. Over the most recent reported fiscal year, revenue declined 2.7%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +95.3% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-75.4%

How far the last close sits under the highest price of the past five years.

Market cap	$2.57B
Trailing P/E	32.7
Price / book	1.2
Price / sales	2.9
FCF yield	1.3%
Dividend yield	—
Gross margin	47.4%
Operating margin	-0.8%
Net margin	-6.3%
Revenue growth (YoY)	-2.7%
Revenue growth (3-yr annual)	+1.9%
EPS growth (YoY)	-26.3%
FCF/share growth (YoY)	—
Beta	1.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

NEOG earnings

Next report: Jan 7, 2027 (Q2 2027, EPS estimate $0.06). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q1 2027	Oct 6, 2026	$0.08	$0.05	+60.0%	$222.80M
Q4 2026	Jul 30, 2026	$0.09	$0.06	+50.0%	$225.30M
Q3 2026	Apr 9, 2026	$0.09	$0.05	+80.0%	$211.20M
Q2 2026	Jan 8, 2026	$0.10	$0.07	+42.9%	$224.69M

NEOG analyst price target

Median target $14.00 from 3 analysts, ranging $14.00 – $14.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live NEOG data on Nama Insights →

NEOG FAQ

Is NEOG a buy?: Nama's AI scorecard currently rates Neogen Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NEOG's P/E ratio?: Neogen trades at a trailing price-to-earnings ratio of 32.7.
When does NEOG report earnings?: Neogen's next scheduled report is on Jan 7, 2027. Analysts expect EPS of $0.06.
What is the NEOG price target?: The median analyst price target from 3 analysts is $14.00, with a range of $14.00 – $14.00.
Is NEOG Shariah compliant?: Nama's AAOIFI-style screen reads Neogen as Not Shariah Compliant. At least one of the three ratios or the industry test failed.